ARTES Biotechnology joins TA101 GOCLIN
A leading consortium of industrial partners has been awarded a grant by the Seventh Framework Program of the European Union for an innovative research and development project “TA101 GOCLIN: Clinical development of TA-101 for the treatment of rheumatoid arthritis“ (#606352). The aim of this Project is to take TA101, a small domain antibody developed by TechnoPhage, into the clinical stage of development for rheumatoid arthritis (RA) and develop a novel mode of administration for the market of biologic therapeutics. The project is forecasted for completion in 2015, with a total duration of 26 months. The total budget is EUR 1,72 million corresponding to a total European funding of EUR 1,36 million.
TA101 GOCLIN has mobilized the critical mass of seven industrial partners from 5 European countries. These partners are from Belgium, France, Germany, The Netherlands and Portugal.
Amspar B.V will design and develop an integrated microneedle patch combination loaded with TA_101. In this regard, Amspar will closely work together with Laboratoires Plasto Santé (expert in pharmaceutical patch development) and MicroCreate BV (microneedle array manufacturing).
Q‑Biologicals NV together with ARTES Biotechnology GmbH will develop a suitable microbial expression host and manufacturing process. cGMP material for clinical trials will be produced by Q‑Biologicals.
Clinical trials will be conducted by SGS Life Science Services.
